We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.70 | 1.61% | 44.15 | 44.33 | 43.96 | 44.13 | 3,104,015 | 01:00:00 |
From May 2022 to May 2024
1139 GMT - GSK PLC is among the most mentioned companies across news items over the past 12 hours, according to Factiva data, after it posted higher sales and profit for the fourth quarter which beat consensus expectations. The British pharma major posted net profit of GBP1.50 billion, up from GBP749 million the year prior, on sales which rose to GBP7.38 billion. Operating profit and earnings per share beat analysts' expectations, coming in at GBP1.87 billion and 36.5 pence, respectively. Analysts had forecast operating profit to be GBP1.49 billion and EPS at 21.2 pence. The company posted record sales of its best-selling shingles vaccine Shingrix, AJ Bell analysts note, adding that 2022 was a landmark year for the company. Dow Jones & Co. owns Factiva. (cecilia.butini@wsj.com)
(END) Dow Jones Newswires
February 01, 2023 06:54 ET (11:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
